Ads
related to: experimental prostate cancer drugs names and side effects- XTANDI® EMBARK Data
Review Xtandi EMBARK Trial Data and
Results.
- Treatment Guidelines
Review NCCN and AUA Guidelines That
Support the Use of XTANDI®.
- HCP Access & Support
Explore HCP Support Information and
Coverage Tools For Patients.
- Clinical Trial Data
View Clinical Data & Results
From a Pivotal Trial for XTANDI®
- XTANDI® EMBARK Data
Search results
Results from the WOW.Com Content Network
Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
Nilutamide (Anandron, Nilandron): Marketed for the treatment of prostate cancer. [3] Very little-used due to a high incidence of interstitial pneumonitis and high rates of several unique and unfavorable side effects such as nausea and vomiting, visual disturbances, and alcohol intolerance.
Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. [8] [9] [10] [15] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer. [2] [10] [9]
Galeterone (developmental code names TOK-001, VN/124-1) is a steroidal antiandrogen which was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. [1] It possesses a unique triple mechanism of action , acting as an androgen receptor antagonist , androgen receptor down regulator, [ 2 ] and CYP17A1 inhibitor , [ 3 ...
Ads
related to: experimental prostate cancer drugs names and side effects